Pfizer CEO Albert Bourla calls the new agreement with the Trump administration “historic,” pledging to offer all medications to Medicaid at “most favored nation” pricing. The deal also includes relocating overseas drug production to the U.S., backed by a three-year tariff exemption. The move aims to ease the burden on American patients, who pay nearly triple the cost of drugs compared to other wealthy nations.